After a year of controversy and complaints, Sen. Elizabeth Warren is asking a federal watchdog to investigate GSK over its ...

The first designs have been released of the housing-led redevelopment of GlaxoSmithKline’s former west London HQ, drawn up by ...

Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company's EMBRACE phase IIb study.1 The ...

US Transthyretin Amyloidosis Treatment Market Growth BURLINGAME, CA, UNITED STATES, March 13, 2025 /EINPresswire / -- The U.S. transthyretin a ...

Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...

GSK's vaccine has just hit the mark in a phase ... all awarded by the European Patent Office and covering recombinant RSV antigens and compositions and methods for making them.

Vaccine hesitancy cost lives during Covid-19—but countries in Central and Eastern Europe can learn from Britain’s, and from ...

The awards are regarded as a ‘mark of excellence’ within the charity health sector and recognise the work that organisations ...

We’ve been here many times for workplace events. We like the Business Design Centre. And we very much like the Workspace ...

The economic impact of a smaller federal government in the region has meant fewer workers, canceled office leases, buildings for sale and some contracts terminated.

Transthyretin Amyloid Cardiomyopathy Treatment Market is estimated to be valued at US$ 1.69 Bn in 2023, and is expected to exhibit a CAGR of 31.1% by 2030. Mr. Shah Coherent Market Insights Pvt. Ltd.